시장보고서
상품코드
1266823

중추신경계(CNS) 바이오마커 : 각종 기술과 세계 시장

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

발행일: | 리서치사: BCC Research | 페이지 정보: 영문 135 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 중추신경계(CNS) 바이오마커 시장 규모는 2022년 57억 달러에서 2022년부터 2027년까지 10.8%의 CAGR로 2027년에는 95억 달러 규모로 성장할 것으로 예측됩니다.

생명과학 연구 부문은 2022년 42억 달러에서 9.9%의 CAGR로 2027년에는 68억 달러 규모로 성장할 것으로 예측됩니다. 또한 임상 진단 부문은 2022년 8억 6,170만 달러에서 14.3%의 CAGR로 2027년에는 17억 달러 규모로 성장할 것으로 예측됩니다.

이 보고서는 세계 중추신경계(CNS) 바이오마커 시장을 조사하고 시장 및 기술 배경, 시장 규모의 추이·예측, 각종 부문·지역별 상세 분석, 신기술·신제품 동향, 경쟁 환경, 주요 기업 개요 등을 정리하고 있습니다.

목차

제1장 소개

제2장 요약 하이라이트

제3장 시장 및 기술 배경

  • 바이오마커의 개요
  • 바이오마커의 분류
  • 바이오마커의 타입
  • 바이오마커의 발견·검증·타당성 확인
  • 중추신경계(CNS)의 개요

제4장 시장 역학

  • 촉진요인
  • 억제요인

제5장 시장 내역 : 질환별

  • 시장 개요
  • 알츠하이머병(AD)
  • AD의 주요 바이오마커
    • 아밀로이드 베타(AB, 베타 아밀로이드 또는 A 베타)
    • 타우 단백질
    • 기타 바이오마커
    • 혈액 기반 AD 바이오마커 검사의 새로운 필요성
  • 파킨슨병(PD)
  • PD의 주요 바이오마커
    • DaTscan(이오플팬 I123 주사)
    • Flourodopa F18(F-도파)
    • 알파시누클레인(α-시누클레인)
    • 기타 바이오마커
  • 다발성 경화증(MS)
  • MS의 주요 바이오마커
    • 뉴로필라멘트 라이트(NfL)
    • 미엘린 염기성 단백질(MBP)
  • 근위축성 측삭 경화증(ALS)
  • 전두측두형 치매(FTD)
  • ALS 및 FTD의 주요 바이오마커
    • TAR DNA 결합 단백질 43(TDP-43)
    • 뉴로필라멘트 경쇄(NfL)
  • 외상성 뇌 손상(TBI) 또는 뇌진탕
  • 외상성 척수 손상(SCI)
  • TBI 또는 SCI의 주요 바이오마커/특징
    • 신경섬유성 산성 단백질(GFAP)
    • 유비퀴틴 C-말단 가수분해효소(UCH-L1)
    • 뉴로필라멘트 헤비(NF-H)와 라이트(NF-L)
    • S100 칼슘 결합 단백질 B(S100B)
  • 기타 질환
    • 희소뇌 질환
  • 세계의 중추신경계(CNS) 바이오마커 시장 : 질환별
    • 알츠하이머병(AD)
    • 파킨슨병(PD)
    • 다발성 경화증(MS)·근위축성 측삭 경화증(ALS)·전두 측두형 치매(FTD)
    • 외상성 뇌 및 척수 손상
    • 기타

제6장 시장 내역 : 용도별

  • 시장 개요
  • 생명과학 연구
  • Drug Discovery & Development
  • 임상 진단
  • 맞춤형 의료
    • 정밀 건강 진단 / 질병 위험 평가
  • 세계의 중추신경계(CNS) 바이오마커 시장 : 용도별
    • 생명과학 연구
    • Drug Discovery & Development
    • 임상 진단
    • 맞춤형 의료

제7장 시장 내역 : 기술 유형별

  • 시장 개요
  • 프로테오믹스
    • 프로테오믹스 기술
  • 이미징
  • 게노믹스
  • 세계의 중추신경계(CNS) 바이오마커 시장 : 기술 유형별
    • 프로테오믹스
    • 이미징
    • 게노믹스

제8장 시장 내역 : 바이오마커 유형별

  • 신경 변성의 주요 바이오마커
    • 아밀로이드 베타(AB, 베타 아밀로이드 또는 A 베타)
    • 타우 단백질
    • 알파시누클레인(α-시누클레인)
    • 시냅스
    • P53 단백질
    • 아포리포단백질 E(APOE) -4
  • 외상성 뇌 및 척수 손상의 주요 바이오마커
    • 신경섬유성 산성 단백질(GFAP)
    • 유비퀴틴 C-말단 가수분해효소(UCH-L1)
    • S100 칼슘 결합 단백질 B(S100B)
    • 뉴로필라멘트 헤비(NF-H)와 라이트(NF-L)
  • 신경 염증의 주요 바이오마커 표적
    • 뇌유래신경영양인자(BDNF)
    • 신경성장인자(NGF)
    • 염증성 사이토카인
    • 세계의 중추신경계(CNS) 바이오마커 시장 : 바이오마커 유형별

제9장 시장 내역 : 지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제10장 COVID-19의 영향

제11장 경쟁 상황

  • 개요
  • 제품 출시/승인
  • 콜라보레이션/파트너십
  • SWOT 분석

제12장 시장에서의 새로운 제품·기술

  • CNS 바이오마커의 혈액검사
  • 타우 단백질에 주목
  • 디지털 바이오마커
  • 임상적으로 중요한 새로운 CNS 바이오마커 후보

제13장 기업 개요

  • ABBOTT LABORATORIES LTD.
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • C2N DIAGNOSTICS, LLC
  • DIADEM SPA
  • EISAI CO. LTD.
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • HU GROUP HOLDINGS INC.
  • LABORATORY CORP. OF AMERICA(LABCORP)
  • MERCK KGAA
  • PERKINELMER INC.
  • QUANTERIX CORP.
  • QUEST DIAGNOSTICS INC.
  • SHIMADZU CORP.
  • SIEMENS HEALTHINEERS AG
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
ksm 23.05.09

Highlights:

The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.

Life science research segment of the global CNS biomarkers market is expected to grow from $4.2 billion in 2022 to $6.8 billion in 2027 at a CAGR of 9.9% for the forecast period of 2022 to 2027.

Clinical diagnostics segment of the global CNS biomarkers market is expected to grow from $861.7 million in 2022 to $1.7 billion in 2027 at a CAGR of 14.3% for the forecast period of 2022 to 2027.

Report Scope:

This study provides a comprehensive analysis of CNS biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the global CNS biomarkers market.

Current and projected product forecasts during the forecast period (2022 to 2027) are discussed. New products approved in 2021 and 2022 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Market figures for 2022 are estimated, except where actual results have been reported.

Included in this report are forecasts by biomarker type, technology type, disease, application, and region from 2022 through 2027. The report also includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.

Report Includes:

  • 43 tables
  • An overview of the global market and technologies for central nervous system (CNS) biomarkers
  • Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Explanation of market drivers, restraints and other forces impacting the global market
  • Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease, multiple sclerosis, and others
  • Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Study Goals and Objectives
  • 1.2 Reasons for Doing This Study
  • 1.3 What's New in This Update?
  • 1.4 Scope of Report
  • 1.5 Methodology and Information Sources
  • 1.6 Geographic Breakdown
  • 1.7 Analyst's Credentials
  • 1.8 BCC Custom Research
  • 1.9 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • 3.1 Overview of Biomarkers
  • 3.2 Classification of Biomarkers
  • 3.3 Types of Biomarkers
  • 3.4 Biomarker Discovery, Verification and Validation
    • 3.4.1 Surrogate Biomarkers/Endpoints
  • 3.5 Overview of Central Nervous System (CNS)

Chapter 4 Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Growing Incidence and Financial Burden of Neurological Disorders
    • 4.1.2 High Unmet Need in Neurodegenerative Disorders
    • 4.1.3 Need to Reduce Drug Development Costs and Failures
    • 4.1.4 Increasing investment in Neuroscience
    • 4.1.5 Developments in Analytical Technologies and Assay Methods
    • 4.1.6 Support from Regulatory Agencies
  • 4.2 Restraints
    • 4.2.1 Technological Challenges
    • 4.2.2 Regulatory and Reimbursement Challenges

Chapter 5 Market Breakdown by Disease

  • 5.1 Market Overview
  • 5.2 Alzheimer's Disease (AD)
    • 5.2.1 AD Pathophysiology
    • 5.2.2 Prevalence and Incidence
  • 5.3 Key Biomarkers of AD
    • 5.3.1 Amyloid-beta (AB, Beta Amyloid, or Abeta)
    • 5.3.2 Tau Protein
    • 5.3.3 Other Biomarkers of AD
    • 5.3.4 Emerging Need for Blood-Based AD Biomarkers Testing
  • 5.4 Parkinson's Disease (PD)
    • 5.4.1 Prevalence and Incidence
  • 5.5 Key Biomarkers of PD
    • 5.5.1 DaTscan (Ioflupane I 123 Injection)
    • 5.5.2 Flourodopa F18 (F-Dopa)
    • 5.5.3 Alpha synuclein (a-synuclein)
    • 5.5.4 Other Biomarkers of PD
  • 5.6 Multiple Sclerosis (MS)
  • 5.7 Key Biomarkers of MS
    • 5.7.1 Neurofilament Light (NfL)
    • 5.7.2 Myelin Basic Protein (MBP)
  • 5.8 Amyotrophic Lateral Sclerosis (ALS)
  • 5.9 Frontotemporal Dementia (FTD)
  • 5.10 Key Biomarkers of ALS and FTD
    • 5.10.1 TAR DNA-Binding Protein 43 (TDP-43)
    • 5.10.2 Neurofilament Light Chain (NfL)
  • 5.11 Traumatic Brain Injury (TBI) or Concussion
  • 5.12 Traumatic Spinal Cord Injury (SCI)
  • 5.13 Key Biomarkers/Hallmarks of TBI or SCI
    • 5.13.1 Glial Fibrillary Acidic Protein (GFAP)
    • 5.13.2 Ubiquitin C-terminal Hydrolase (UCH-L1)
    • 5.13.3 Neurofilament-Heavy (NF-H) and Light (NF-L)
    • 5.13.4 S100 Calcium-binding Protein B (S100B)
  • 5.14 Other Diseases
    • 5.14.1 Rare Brain Diseases
  • 5.15 Global Market for CNS Biomarkers by Disease
    • 5.15.1 Alzheimer's Disease (AD)
    • 5.15.2 Parkinson's Disease (PD)
    • 5.15.3 Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD)
    • 5.15.4 Traumatic Brain and Spinal Cord Injuries
    • 5.15.5 Others

Chapter 6 Market Breakdown by Application

  • 6.1 Market Overview
  • 6.2 Life Science Research
  • 6.3 Drug Discovery and Development
  • 6.4 Clinical Diagnostics
  • 6.5 Personalized Medicine
    • 6.5.1 Precision Health Screening/Disease Risk Assessment
  • 6.6 Global Market for CNS Biomarkers, by Application
    • 6.6.1 Life Science Research
    • 6.6.2 Drug Discovery and Development
    • 6.6.3 Clinical Diagnostics
    • 6.6.4 Personalized Medicine

Chapter 7 Market Breakdown by Technology Type

  • 7.1 Market Overview
  • 7.2 Proteomics
    • 7.2.1 Proteomics Technologies
  • 7.3 Imaging
  • 7.4 Genomics
  • 7.5 Global Market for CNS Biomarkers, by Technology Type
    • 7.5.1 Proteomics
    • 7.5.2 Imaging
    • 7.5.3 Genomics

Chapter 8 Market Breakdown by Biomarker Type

  • 8.1 Key Biomarkers of Neurodegeneration
    • 8.1.1 Amyloid beta (AB, beta amyloid, or Abeta)
    • 8.1.2 Tau Proteins
    • 8.1.3 Alpha synuclein (a-synuclein)
    • 8.1.4 Synapses
    • 8.1.5 P53 protein
    • 8.1.6 Apolipoprotein E (APOE)-4
  • 8.2 Key Biomarkers of Traumatic Brain and Spinal Injuries
    • 8.2.1 Glial Fibrillary Acidic Protein (GFAP)
    • 8.2.2 Ubiquitin C-terminal hydrolase (UCH-L1)
    • 8.2.3 S100 Calcium-binding Protein B (S100B)
    • 8.2.4 Neurofilament-Heavy (NF-H) and Light (NF-L)
  • 8.3 Key Biomarker Targets for Neuroinflammation
    • 8.3.1 Brain-derived Neurotrophic Factor (BDNF)
    • 8.3.2 Nerve Growth Factor (NGF)
    • 8.3.3 Proinflammatory Cytokines
    • 8.3.4 Global CNS Biomarkers Market by Biomarker Type

Chapter 9 Market Breakdown by Region

  • 9.1 Global Market for CNS Biomarkers by Region
  • 9.2 North America
  • 9.3 Europe
  • 9.4 Asia-Pacific
  • 9.5 Rest of the World (RoW)

Chapter 10 Impact of COVID-19

  • 10.1 Overview
  • 10.2 Impact on CNS Biomarkers Market

Chapter 11 Competitive Landscape

  • 11.1 Overview
  • 11.2 Product Launches/Approvals
  • 11.3 Collaborations/Partnerships
  • 11.4 SWOT Analysis for Global CNS Biomarker Industry

Chapter 12 Emerging Products/Technologies in the Market

  • 12.1 Blood Tests for CNS Biomarkers
  • 12.2 Focus on Tau Protein
  • 12.3 Digital Biomarkers
  • 12.4 Emerging Clinically Relevant CNS Biomarker Candidates

Chapter 13 Company Profiles

  • ABBOTT LABORATORIES LTD.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES INC.
  • C2N DIAGNOSTICS, LLC
  • DIADEM SPA
  • EISAI CO. LTD.
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • H.U. GROUP HOLDINGS INC.
  • LABORATORY CORP. OF AMERICA (LABCORP)
  • MERCK KGAA
  • PERKINELMER INC.
  • QUANTERIX CORP.
  • QUEST DIAGNOSTICS INC.
  • SHIMADZU CORP.
  • SIEMENS HEALTHINEERS AG
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제